Effect of dimethyl fumarate (Tecfidera) on the association between fatigue and fatigability in relapsing-remitting MS patients* - Tecfidera and Fatigue and fatigability in RRMS / DMF_FF_RRMS

niversitair Medisch Centrum Groningen0 个研究点目标入组 30 人开始时间: 待定最近更新: 2024年4月15日

试验速览

暂无简介。

•* Informed consent
•* Age: 18 * 55 years
•Additional criteria for pwRRMS:
•* A diagnosis of RRMS according to the McDonald criteria
•* A baseline Expanded Disability Status Scale <4.5
•* Newly initiating treatment with DMF (Tecfidera) under routine clinical care
•* Adequate hand function that allows subjects to utilize the force transducer (as determined by the neurologist).

•* History of alcohol or drug abuse or current alcohol or drug abuse
•* Neurologic condition unrelated to MS Psychiatric disorder (including affective disorders).
•* Other conditions/diseases influencing fatigue:
•o Chronic fatigue syndrome
•* Primary immunodeficiency.
•* Treatment with steroids within one month prior to inclusion
•* Participation in an investigational drug study within 3 months prior to inclusion
•* A MS relapse within one month prior to inclusion
•* Medication:
•o 4-aminopyridine or another form of fampridine
•o antidepressant

发起方